InhaleRx (ASX:IRX) Accounts Payable & Accrued Expense : A$0.74 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InhaleRx Accounts Payable & Accrued Expense?

InhaleRx's quarterly accounts payable & accrued expense declined from Dec. 2023 (A$0.35 Mil) to Jun. 2024 (A$0.32 Mil) but then increased from Jun. 2024 (A$0.32 Mil) to Dec. 2024 (A$0.74 Mil).

InhaleRx's annual accounts payable & accrued expense increased from Dec. 2022 (A$0.18 Mil) to Dec. 2023 (A$0.35 Mil) and increased from Dec. 2023 (A$0.35 Mil) to Dec. 2024 (A$0.74 Mil).

InhaleRx Accounts Payable & Accrued Expense Historical Data

The historical data trend for InhaleRx's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InhaleRx Accounts Payable & Accrued Expense Chart

InhaleRx Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.29

0.23

0.18

0.35

0.74

InhaleRx Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial												0.18	0.37	0.35	0.32	0.74

InhaleRx Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

InhaleRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InhaleRx Ltd (ASX:IRX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/- Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000

Website

https://www.inhalerx.com.au

InhaleRx Ltd is an Australian biotechnology company specialising in precision medicine delivered through inhalation. Its novel drug device combinations target the treatment of BTcP and PD to help improve the quality of life of sufferers of these diseases. The medications are being developed to be delivered via a pressurised metered dose inhaler (pMDI) in a fixed dose, providing a convenient and effective mode of administration. The company's clinical pipeline comprises IRX211, a THC-based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering from acute episodic bursts of breakthrough pain; and IRX616a, for the treatment of panic disorders.

InhaleRx Headlines

No Headlines